111Indium-labeled monoclonal antibody K1: biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin - PubMed (original) (raw)
111Indium-labeled monoclonal antibody K1: biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin
R Hassan et al. Int J Cancer. 1999.
Abstract
The monoclonal antibody (MAb) K1 is a murine IgG1 that recognizes mesothelin, a differentiation antigen present on mesothelium which is highly expressed on cancers derived from mesothelium, including most ovarian cancers and epithelioid mesotheliomas. MAb K1 was conjugated to 2-(p-isothiocyanatobenzyl)-cyclohexyl- diethylenetriaminepentaacetic acid and labeled with 111In. The biodistribution of 111In-K1 was studied in athymic nude mice bearing 2 s.c. tumors, one expressing a stably transfected plasmid encoding mesothelin and one composed of the parental untransfected A431 epidermoid carcinoma cells which do not express mesothelin. Tumor-bearing mice were given an i.v. injection of 111In-K1 and killed at different time points to determine the uptake of radiolabeled antibody. Significantly higher uptake was seen in antigen-positive tumors at all time points, with peak values at 72 hr (52.9% vs. 8% of the injected dose/g tissue for antigen-positive and antigen-negative tumors, respectively). Uptake in antigen-positive tumors was higher than the blood level at all time points, and the tumors contained a high level of the radiolabeled MAb even at 7 days (28.6% of the injected dose/g tumor).
Similar articles
- Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma.
Hassan R, Viner JL, Wang QC, Margulies I, Kreitman RJ, Pastan I. Hassan R, et al. J Immunother. 2000 Jul-Aug;23(4):473-9. doi: 10.1097/00002371-200007000-00011. J Immunother. 2000. PMID: 10916757 - Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody.
Shin IS, Lee SM, Kim HS, Yao Z, Regino C, Sato N, Cheng KT, Hassan R, Campo MF, Albone EF, Choyke PL, Pastan I, Paik CH. Shin IS, et al. Nucl Med Biol. 2011 Nov;38(8):1119-27. doi: 10.1016/j.nucmedbio.2011.05.003. Epub 2011 Jul 7. Nucl Med Biol. 2011. PMID: 21741258 Free PMC article. - Preclinical evaluation of 111In-labeled B3 monoclonal antibody: biodistribution and imaging studies in nude mice bearing human epidermoid carcinoma xenografts.
Camera L, Kinuya S, Pai LH, Garmestani K, Brechbiel MW, Gansow OA, Paik CH, Pastan I, Carrasquillo JA. Camera L, et al. Cancer Res. 1993 Jun 15;53(12):2834-9. Cancer Res. 1993. PMID: 8504427 - Pharmacokinetics, biodistribution, and gamma camera imaging of 111In-KC-4G3 murine monoclonal antibody in athymic nude mice with or without human tumor xenografts.
Longley C, Furmanski P, Dienhart DG, Lear J, Bloedow D, Kasliwal R, Bunn PA Jr. Longley C, et al. Cancer Res. 1990 Sep 15;50(18):5954-61. Cancer Res. 1990. PMID: 2393864 - 111In-Diethylenetriaminepentaacetic acid-2-(_p_-isothiocyanatobenzyl)-6-methyl-B3 monoclonal antibody.
Leung K. Leung K. 2009 Mar 17 [updated 2009 May 13]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2009 Mar 17 [updated 2009 May 13]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641590 Free Books & Documents. Review.
Cited by
- Mesothelin: An Immunotherapeutic Target beyond Solid Tumors.
Faust JR, Hamill D, Kolb EA, Gopalakrishnapillai A, Barwe SP. Faust JR, et al. Cancers (Basel). 2022 Mar 18;14(6):1550. doi: 10.3390/cancers14061550. Cancers (Basel). 2022. PMID: 35326701 Free PMC article. Review. - Immunotoxins: From Design to Clinical Application.
Kreitman RJ, Pastan I. Kreitman RJ, et al. Biomolecules. 2021 Nov 15;11(11):1696. doi: 10.3390/biom11111696. Biomolecules. 2021. PMID: 34827694 Free PMC article. - Immunotherapy-based targeting of MSLN+ activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosis.
Nishio T, Koyama Y, Liu X, Rosenthal SB, Yamamoto G, Fuji H, Baglieri J, Li N, Brenner LN, Iwaisako K, Taura K, Hagood JS, LaRusso NF, Bera TK, Pastan I, Brenner DA, Kisseleva T. Nishio T, et al. Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):e2101270118. doi: 10.1073/pnas.2101270118. Proc Natl Acad Sci U S A. 2021. PMID: 34253615 Free PMC article. - A Novel 89Zr-labeled DDS Device Utilizing Human IgG Variant (scFv): "Lactosome" Nanoparticle-Based Theranostics for PET Imaging and Targeted Therapy.
Lim MSH, Ohtsuki T, Takenaka F, Kobayashi K, Akehi M, Uji H, Kobuchi H, Sasaki T, Ozeki E, Matsuura E. Lim MSH, et al. Life (Basel). 2021 Feb 18;11(2):158. doi: 10.3390/life11020158. Life (Basel). 2021. PMID: 33670777 Free PMC article. Review. - Construction and Preclinical Evaluation of 211At Labeled Anti-mesothelin Antibodies as Potential Targeted Alpha Therapy Drugs.
Wang X, Ma W, Liu W, Ma H, Yang Y, Wang Y, Liu N, Yang G. Wang X, et al. J Radiat Res. 2020 Sep 8;61(5):684-690. doi: 10.1093/jrr/rraa049. J Radiat Res. 2020. PMID: 32648573 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources